Essex Woodlands Health Ventures Cut Its Abiomed (ABMD) Stake by $56.10 Million as Stock Value Rose; Facebook (FB) Shareholder Teewinot Capital Advisers Trimmed Holding

April 26, 2018 - By Migdalia James

Facebook, Inc. (NASDAQ:FB) Logo

Essex Woodlands Health Ventures Inc decreased its stake in Abiomed Inc (ABMD) by 31.69% based on its latest 2017Q4 regulatory filing with the SEC. Essex Woodlands Health Ventures Inc sold 300,000 shares as the company’s stock rose 49.46% while stock markets declined. The hedge fund held 646,818 shares of the health care company at the end of 2017Q4, valued at $121.22 million, down from 946,818 at the end of the previous reported quarter. Essex Woodlands Health Ventures Inc who had been investing in Abiomed Inc for a number of months, seems to be less bullish one the $13.45B market cap company. The stock increased 3.57% or $10.46 during the last trading session, reaching $303.66. About 161,969 shares traded. ABIOMED, Inc. (NASDAQ:ABMD) has risen 128.67% since April 26, 2017 and is uptrending. It has outperformed by 117.12% the S&P500.

Michael Moriarty decreased its stake in Facebook Inc (FB) by 11.57% based on its latest 2017Q4 regulatory filing with the SEC. Teewinot Capital Advisers Llc sold 5,800 shares as the company’s stock declined 14.10% with the market. The hedge fund run by Michael Moriarty held 44,326 shares of the technology company at the end of 2017Q4, valued at $7.82M, down from 50,126 at the end of the previous reported quarter. Teewinot Capital Advisers Llc who had been investing in Facebook Inc for a number of months, seems to be less bullish one the $505.68B market cap company. The stock increased 9.22% or $14.72 during the last trading session, reaching $174.41. About 48.48M shares traded or 34.76% up from the average. Facebook, Inc. (NASDAQ:FB) has risen 8.48% since April 26, 2017 and is uptrending. It has underperformed by 3.07% the S&P500.

Analysts await ABIOMED, Inc. (NASDAQ:ABMD) to report earnings on May, 3 before the open. They expect $0.64 EPS, up 93.94% or $0.31 from last year’s $0.33 per share. ABMD’s profit will be $28.34M for 118.62 P/E if the $0.64 EPS becomes a reality. After $0.70 actual EPS reported by ABIOMED, Inc. for the previous quarter, Wall Street now forecasts -8.57% negative EPS growth.

Since February 20, 2018, it had 0 insider purchases, and 1 insider sale for $5.41 million activity.

Investors sentiment decreased to 1.18 in Q4 2017. Its down 0.12, from 1.3 in 2017Q3. It fall, as 19 investors sold ABMD shares while 110 reduced holdings. 55 funds opened positions while 97 raised stakes. 36.44 million shares or 5.39% less from 38.51 million shares in 2017Q3 were reported. Enterprise Finance Services Corp reported 10 shares or 0% of all its holdings. Metropolitan Life Communication New York has invested 0.03% in ABIOMED, Inc. (NASDAQ:ABMD). Cibc Bancorp Usa accumulated 1,550 shares or 0.04% of the stock. Glenmede Na owns 2,781 shares for 0% of their portfolio. Jpmorgan Chase & stated it has 62,251 shares. Chicago Equity Ptnrs Limited Liability Corporation has invested 0.01% in ABIOMED, Inc. (NASDAQ:ABMD). Marshall Wace Ltd Liability Partnership has invested 0.07% in ABIOMED, Inc. (NASDAQ:ABMD). Duncker Streett & Incorporated invested in 175 shares. First Quadrant Lp Ca accumulated 6,474 shares or 0.02% of the stock. Washington Capital Mgmt holds 0.38% in ABIOMED, Inc. (NASDAQ:ABMD) or 2,000 shares. Spectrum Management Group Inc reported 0% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD). Goldman Sachs Grp Incorporated owns 508,949 shares. Fred Alger Mngmt has 0.42% invested in ABIOMED, Inc. (NASDAQ:ABMD) for 499,294 shares. Weaver C Barksdale And Associates has 0% invested in ABIOMED, Inc. (NASDAQ:ABMD). Capital One Association owns 2,491 shares.

Among 15 analysts covering Abiomed (NASDAQ:ABMD), 12 have Buy rating, 0 Sell and 3 Hold. Therefore 80% are positive. Abiomed had 35 analyst reports since August 4, 2015 according to SRatingsIntel. On Wednesday, December 7 the stock rating was initiated by Guggenheim with “Buy”. Leerink Swann maintained it with “Outperform” rating and $125 target in Wednesday, May 4 report. The firm has “Buy” rating given on Thursday, September 21 by Jefferies. The stock of ABIOMED, Inc. (NASDAQ:ABMD) earned “Neutral” rating by BTIG Research on Monday, October 16. The firm earned “Buy” rating on Thursday, June 29 by Jefferies. The rating was maintained by Jefferies with “Buy” on Thursday, February 1. Northland Capital maintained ABIOMED, Inc. (NASDAQ:ABMD) rating on Wednesday, August 5. Northland Capital has “Market Perform” rating and $80 target. The company was maintained on Tuesday, June 6 by Jefferies. The firm has “Buy” rating by Jefferies given on Thursday, August 3. Leerink Swann maintained the shares of ABMD in report on Thursday, October 12 with “Buy” rating.

Teewinot Capital Advisers Llc, which manages about $260.49 million and $237.24 million US Long portfolio, upped its stake in Controladora Vuela Cia De Av (NYSE:VLRS) by 1.05M shares to 2.27M shares, valued at $18.19 million in 2017Q4, according to the filing.

Since December 7, 2017, it had 0 insider buys, and 42 selling transactions for $1.47 billion activity. 55,000 shares valued at $9.18M were sold by Sandberg Sheryl on Wednesday, April 18. On Tuesday, January 9 the insider Schroepfer Michael Todd sold $7.14M. FISCHER DAVID B. had sold 17,830 shares worth $3.29M. Shares for $2.66M were sold by Wehner David M.. Koum Jan sold 1.25 million shares worth $221.33 million. 750 shares were sold by Stretch Colin, worth $134,125 on Tuesday, December 12.

Facebook, Inc. (NASDAQ:FB) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>